Nanexa (NANEXA.ST) Stock Analysis & AI Equity Report
Nanexa (NANEXA.ST) overview
Nanexa (NANEXA.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Nanexa reported revenue of SEK 36.1m and operating profit of SEK -15.5m; the year-end share price was 4.45 SEK and market capitalisation was SEK 694m. Nanexa is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Nanexa's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Nanexa
Nanexa AB (publ) is a Swedish pharmaceutical company developing injectable drug products based on its proprietary PharmaShell® drug delivery platform. The company works on long-acting injectable formulations and runs own product projects alongside collaboration agreements with other pharmaceutical companies. Its activities are centered on drug formulation, development, and supporting clinical and manufacturing work in Uppsala.
Generate the Nanexa report
Nanexa is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Nanexa and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.